Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 337

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Open access
Pusztai, Lajos, Yau, Christina, Wolf, Denise M., Han, Hyo S., Du, Lili, Wallace, Anne M., String-Reasor, Erica, Boughey, Judy C., Chien, A. Jo, Elias, Anthony D., Beckwith, Heather, Nanda, Rita, Albain, Kathy S., Clark, Amy S., Kemmer, Kathleen, Kalinsky, Kevin, Isaacs, Claudine, Thomas, Alexandra, Shatsky, Rebecca, Helsten, Theresa L., Forero-Torres, Andres, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emmanuel F., Wulfkuhle, Julia D., Asare, Smita M., Wilson, Amy, Singhrao, Ruby, Sit, Laura, Hirst, Gillian L., Berry, Scott, Sanil, Ashish, Asare, Adam L., Matthews, Jeffrey B., Perlmutter, Jane, Melisko, Michelle, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Yee, Doug, van’t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.·2021·Cancer Cell

Abstract

SUMMARY The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (DOP) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast cancer. Seventy-three participants were randomized to DOP and 299 to standard-of-care (paclitaxel) control. DOP increased pathologic complete response (pCR) rates in all HER2-negative (20 to 37%), hormone receptor (HR)-positive/HER2-negative (14% to 28%), and triple negative (TNBC) (27% to 47%). In HR-positive/HER2-negative cancers, MammaPrint ultra-high (MP2) cases benefited selectively from DOP (pCR 64% vs 22%), no benefit was seen in MP1 cancers (pCR 9% vs 10%). Overall,12.3% of patients in DOP arm experienced immune-related grade 3 adverse events vs. 1.3% in control. Gene expression signatures associated with immune response were positively associated with pCR in both arms, while a mast cell signature was associated with non-pCR. DOP has superior efficacy over standard neoadjuvant chemotherapy in HER2-negative breast cancer, particularly in a highly sensitive subset of high-risk HR-positive/HER2-negative patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.05.009

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 337

Metadata

Authors
Pusztai, L., Yau, C., Wolf, D. M., Han, H. S., Du, L., Wallace, A. M., String-Reasor, E., Boughey, J. C., Chien, A. J., Elias, A. D., Beckwith, H., Nanda, R., Albain, K. S., Clark, A. S., Kemmer, K., Kalinsky, K., Isaacs, C., Thomas, A., Shatsky, R., Helsten, T. L., Forero-Torres, A., Liu, M. C., Brown-Swigart, L., Petricoin, E. F., Wulfkuhle, J. D., Asare, S. M., Wilson, A., Singhrao, R., Sit, L., Hirst, G. L., Berry, S., Sanil, A., Asare, A. L., Matthews, J. B., Perlmutter, J., Melisko, M., Rugo, H. S., Schwab, R. B., Symmans, W. F., Yee, D., van’t Veer, L. J., Hylton, N. M., DeMichele, A. M., Berry, D. A., & Esserman, L. J.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-07
Volume
39
Issue
7
Pages
989-998.e5
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3172174831
Cited by
337
References
31
FWCI
16.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. https://app.cochat.ai/papers/10.1016/j.ccell.2021.05.009
The paper
Pusztai, L., Yau, C., Wolf, D. M., Han, H. S., Du, L., Wallace, A. M., String-Reasor, E., Boughey, J. C., Chien, A. J., Elias, A. D., Beckwith, H., Nanda, R., Albain, K. S., Clark, A. S., Kemmer, K., Kalinsky, K., Isaacs, C., Thomas, A., Shatsky, R., . . . Esserman, L. J. (2021). Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.05.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.